Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ARV-110 |
Synonyms | |
Therapy Description |
ARV-110 is bifunctional molecule that targets androgen receptor (AR) for proteolytic degradation resulting in reduced target gene expression, potentially leading to decreased tumor growth inhibition and apoptosis (Journal of Clinical Oncology 37, no. 7_suppl (March 1 2019) 259-259, PMID: 32503798). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ARV-110 | ARV110|ARV 110|Bavdegalutamide | Hormone - Anti-androgens 54 | ARV-110 is bifunctional molecule that targets androgen receptor (AR) for proteolytic degradation resulting in reduced target gene expression, potentially leading to decreased tumor growth inhibition and apoptosis (Journal of Clinical Oncology 37, no. 7_suppl (March 1 2019) 259-259, PMID: 32503798). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03888612 | Phase I | ARV-110 | A Phase 1 Clinical Trial of ARV-110 in Patients With Metastatic Castration-resistant Prostate Cancer. (mCRPC) | Active, not recruiting | USA | 0 |